Lesson From Residency Translated
171161711617116
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Adam Friedman, professor and chair of dermatology at GW School of Medicine and Health Sciences, on life lessons from his residency and career. Dr. Friedman provides his tips for remaining calm during the craziest of office visits. …
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Adam Friedman, professor and chair of dermatology at GW School of Medicine and Health Sciences, on life lessons from his residency and career. Dr. Friedman provides his tips for remaining calm during the craziest of office visits. … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Ted Rosen (Professor, Vice-Chair of Dermatology, and Chief of Dermatology at the Houston Veterans Affairs Medical Center) on his favorite off-label treatment pearls. Watch as he shares how to use indomethacin for the angry red scrot … 
Androgenic alopecia (AGA) is one of the most common forms of hair loss and represents a frequently faced disabling concern in dermatology visits. Targeting the 5α-dihydrotestosterone (DHT) pathway has been shown to be an efficacious mechanism of action, with finasteride being the only systemic FDA-approved drug to treat male AGA. Recently, its sister drug, dutasteride, has been increasingly utili … 